How to implement the modified international normalized ratio for cirrhosis (INRliver) for model for end-stage liver disease calculation

Hepatology

Volumn 47, Issue 4, 2008, Pages 1423-1424

  Tripodi, Armando ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN;

BLOOD CLOTTING DISORDER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOTEST;

HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; PROTHROMBIN TIME; SEVERITY OF ILLNESS INDEX;

EID: 42249099002     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21989     Document Type: Letter

References (8)

1. Marlar RA. Determining the model for end-stage liver disease with better accuracy: neutralizing the international normalized ratio pitfalls. HEPATOLOGY 2007;46:295-296.
2. liver) normalizes prothrombin time results for model for end-stage liver disease calculation. HEPATOLOGY 2007;46:520-527.
3. Bellest L, Eschwege V, Poupon R, Chazoullieres O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. HEPATOLOGY 2007;46:528-534.
4. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al., for the United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003;124:91-96.
5. Trotter JF, Brimhall B, Arjal R. Specific laboratory methodologies achieve higher model for end-stage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000.
6. van den Besselaar AMHP, Poller L, Tripodi A. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy. WHO Tech Rep Ser 1999;889:64-93.
7. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007;26:141-148.
8. van den Besseaar AMHP, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L, et al., for the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH. Guidelines on preparation, certification and use of certified plasmas for ISI calibration and INR derermination. J Thromb Haemost 2004;2:1946-1953.